Polyunsaturated Fatty Acid Levels and Their Relationship With Peak Exercise Measures in HFpEFCIRCULATIONIF38.62023-11-070PRE
GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeysCELL REPORTS MEDICINEIF10.62021-05-0154OAAI
Growth differentiation factor 15 as a potential therapeutic for treating obesityMOLECULAR METABOLISMIF6.62021-04-0135OAAI
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical modelsSCIENCE TRANSLATIONAL MEDICINEIF14.62018-12-19157OAAI
FGF21 acts as a negative regulator of bile acid synthesisJOURNAL OF ENDOCRINOLOGYIF3.92018-05-0147OAAI
Long-acting MIC-1/GDF15 molecules to treat obesity: Evidence from mice to monkeysSCIENCE TRANSLATIONAL MEDICINEIF14.62017-10-18174PREAI
Discovery and Structure-Guided Optimization of Diarylmethanesulfonamide Disrupters of Glucokinase-Glucokinase Regulatory Protein (GK-GKRP) Binding: Strategic Use of a N → S (nN → σ*S-X) Interaction for Conformational ConstraintJOURNAL OF MEDICINAL CHEMISTRYIF6.82015-12-0136OAAI
Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 5. A Novel Aryl Sulfone Series, Optimization Through Conformational AnalysisJOURNAL OF MEDICINAL CHEMISTRYIF6.82015-06-0125PREAI
Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 4. Exploration of a Novel Binding PocketJOURNAL OF MEDICINAL CHEMISTRYIF6.82014-07-0813PREAI
Small Molecule Disruptors of the Glucokinase Glucokinase Regulatory Protein Interaction: 3. Structure Activity Relationships within the Aryl Carbinol Region of the N-Arylsulfonamido-N'-arylpiperazine SeriesJOURNAL OF MEDICINAL CHEMISTRYIF6.82014-03-3155PREAI
Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 1. Discovery of a Novel Tool Compound for in Vivo Proof-of-Concept (vol 57, pg 309, 2014)JOURNAL OF MEDICINAL CHEMISTRYIF6.82014-02-280PREAI
Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 2. Leveraging Structure-Based Drug Design to Identify Analogues with Improved Pharmacokinetic ProfilesJOURNAL OF MEDICINAL CHEMISTRYIF6.82014-01-0922PREAI
Small Molecule Disruptors of the Glucokinase-Glucokinase Regulatory Protein Interaction: 1. Discovery of a Novel Tool Compound for in Vivo Proof-of-ConceptJOURNAL OF MEDICINAL CHEMISTRYIF6.82014-01-0936PREAI
Lack of Overt FGF21 Resistance in Two Mouse Models of Obesity and Insulin ResistanceENDOCRINOLOGYIF3.32012-01-01175OA
Synthesis and Evaluation of the Metabolites of AMG 221, a Clinical Candidate for the Treatment of Type 2 DiabetesACS MEDICINAL CHEMISTRY LETTERSIF42011-09-1915OA
Discovery of a Potent, Orally Active 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor for Clinical Study: Identification of (S)-2-(1S,2S,4R)-Bicyclo[2.2.1]heptan-2-ylamino)-5-isopropyl-5-methylthiazol-4(5H)-one (AMG 221)JOURNAL OF MEDICINAL CHEMISTRYIF6.82010-05-1374PREAI
Antidiabetic effects of 11β-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosisDIABETES OBESITY & METABOLISMIF5.72009-05-2827PREAI
Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese MiceDIABETESIF7.52009-01-011.1KOAAI
Time of the day for 11β-HSD1 inhibition plays a role in improving glucose homeostasis in DIO miceDIABETES OBESITY & METABOLISMIF5.72008-12-2926PREAI
Further Studies with the 2-Amino-1,3-thiazol-4(5H)-one Class of 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors: Reducing Pregnane X Receptor Activity and Exploring Activity in a Monkey Pharmacodynamic ModelJOURNAL OF MEDICINAL CHEMISTRYIF6.82008-11-1931PREAI